MRKRHealthcare · BiotechnologyMRKR Stock Forecast: Marker Therapeutics, Inc. Price Predictions for 2026-2027
The 3 Wall Street analysts covering Marker Therapeutics, Inc. hold a median 12-month price target of $8 — +595.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 54 of 100 as at 12 Sept 2026 — in the upper half.
MRKR stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Marker Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (89): Smaller than most of the companies we track.
Quality (18): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
MRKR stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on MRKR, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +595.7% from it.
Of the 19 most recent actions, 1 moved their price target up and 4 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 8 Dec 2025 | HC Wainwright & Co. | Initiates | Buy | $10 |
| 1 Apr 2025 | WBB Securities | Reiterates | Strong Buy | — |
| 5 Mar 2025 | Canaccord Genuity | Initiates | Buy | — |
| 21 Oct 2024 | Ladenburg Thalmann | Maintains | Buy | $11 → $19 |
| 30 Apr 2024 | Ladenburg Thalmann | Initiates | Buy | — |
| 17 Feb 2022 | Roth Capital | Downgrade | Neutral | $3.00 → $1.00 |
| 25 Mar 2021 | Piper Sandler | Initiates | Overweight | — |
| 19 Mar 2021 | Cantor Fitzgerald | Initiates | Overweight | — |
| 18 Mar 2021 | Cantor Fitzgerald | Initiates | Overweight | — |
| 12 May 2020 | Piper Sandler | Downgrade | Neutral | $5.00 → $2.50 |
| 13 Nov 2019 | Janney Capital | Maintains | Buy | — |
| 13 Nov 2019 | Janney Montgomery Scott | Maintains | Buy | $15 → $10 |
| 13 Nov 2019 | Piper Jaffray | Maintains | Overweight | — |
| 13 Nov 2019 | Piper Sandler | Maintains | Overweight | $10 → $6.00 |
| 3 July 2019 | Oppenheimer | Initiates | Outperform | — |
| 30 May 2019 | Roth Capital | Initiates | Buy | — |
| 29 Mar 2019 | WBB Securities | Upgrade | Strong Buy | — |
| 1 Mar 2019 | Janney Capital | Initiates | Buy | — |
| 1 Mar 2019 | Janney Montgomery Scott | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. MRKR appears on the weeks it earns a place.
MRKR vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 11 Sept 2026, Marker Therapeutics, Inc. returned +18.6% against +17.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
MRKR analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Marker Therapeutics, Inc. (MRKR) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −1.5×
- Price / sales
- 5.4×
- Price / book
- 1.6×
- EV / EBITDA
- −0.7×
Cheaper than 84% of US stocks
Cheaper than 23% of US stocks
Cheaper than 54% of US stocks
Cheaper than 65% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- −268.0%
- Net margin
- −245.5%
Higher than 9% of US stocks
Higher than 2% of US stocks
- Return on equity
- −76.9%
- Return on assets
- −40.5%
- Dividend yield
- —
Higher than 16% of US stocks
Higher than 10% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
Marker Therapeutics, Inc. (MRKR) statistics: revenue, profit & scale
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Marker Therapeutics, Inc. has a market value of $19.2M and an enterprise value of $7.8M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$8.7M.
Free cash flow in the twelve months to 30 June 2026: −$9.8M.
Trailing P/E: −1.5×; forward P/E: −2.2× — the forward figure prices analyst consensus estimates, not reported earnings.
Marker Therapeutics, Inc. employs 5 people.
Data provided by Twelve Data
MRKR vs competitors
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Marker Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Frequently asked questions about MRKR stock
What is the MRKR stock price forecast for 2026-2027?
The 3 Wall Street analysts covering Marker Therapeutics, Inc. have a median 12-month price target of $8, with estimates ranging from $5.6 to $10. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is MRKR stock a buy right now?
Of the 3 analysts covering Marker Therapeutics, Inc., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Marker Therapeutics, Inc. 54 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank MRKR?
As at 12 Sept 2026, Marker Therapeutics, Inc. ranks 54 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (89 of 100).
Will MRKR stock go up?
No one can know that. What the data says: the median 12-month target from 3 analysts implies +595.7% from the last close, and Ticker Nerd's factor model ranks Marker Therapeutics, Inc. 54 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the MRKR stock forecast for 2030?
No analyst covering Marker Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MRKR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5.6 to $10 over the next 12 months.
How has MRKR stock performed over the past year?
Marker Therapeutics, Inc. returned +18.6% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Marker Therapeutics, Inc. do?
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company focused on developing T cell-based immunotherapies for blood cancers and solid tumors.
About Marker Therapeutics, Inc.
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company focused on developing T cell-based immunotherapies for blood cancers and solid tumors. Its core platform uses non-genetically engineered tumor-specific T cells designed to recognize multiple tumor-associated antigens, with the goal of creating broader anti-cancer activity. The company’s current pipeline includes product candidates such as MT-601, being studied in lymphoma and pancreatic cancer, and MT-401-OTS, being evaluated in acute myeloid leukemia and myelodysplastic syndromes. Marker Therapeutics also explores peptide-based vaccine approaches as part of its cancer treatment portfolio. Headquartered in Houston, Texas, the company operates in the biotechnology sector and serves the specialized area of cell therapy research and development, where its work supports the advancement of next-generation treatments for difficult-to-treat malignancies.
CEO Dr. Juan F. Vera M.D. · 5 employees · United States · https://markertherapeutics.com